A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adrenocortical carcinoma
- Focus Therapeutic Use
- 07 Jan 2019 Planned End Date changed from 1 Feb 2021 to 1 Feb 2020.
- 26 Feb 2018 Status changed from not yet recruiting to recruiting.
- 13 Feb 2018 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.